Paxlovid, the antiviral drug designed to reduce the risk of death and hospitalization from COVID-19, may also help cut the chances a person will develop long COVID.
People who took Paxlovid had a 26% reduced risk of developing symptoms of long COVID such as fatigue and shortness of breath, according to theResearchers looked at the medical records of 56,340 people in the VA system who tested positive for COVID from March 1, 2022, to June 30, 2022. All of them had at least one risk factor for long COVID, such as being over 60, a smoker, or having had cancer.
Taking Paxlovid also resulted in a 48% reduced risk of death and a 30% reduced risk of post-acute hospitalization, the study said.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: